

Indications

EVACLIO™ can be applied to diseases that are suggested to be caused by proteins whose molecular weight is comparable to or less than albumin.

- (e.g.)
- Hepatic Failure
 - Sepsis
 - Myoneuropathic Metabolic Syndrome (MNMS)
 - Rhabdomyolysis
 - Multiple Myeloma (Bence-Jones Type)
 - Some Cases of Focal Segmental Glomerular Sclerosis (FSGS)

Specifications

Model		1.0m ²	EC-1C10	EC-2C10	EC-3C10	EC-4C10
		2.0m ²	EC-1C20	EC-2C20	EC-3C20	EC-4C20
Hollow fiber	Material	Ethylene vinyl alcohol copolymer				
	Inner diameter (μm)	175				
	Wall thickness (μm)	40				
Housing	Material	Polycarbonate resin				
	Membrane surface area (m ²)	1.0		2.0		
	Outer dimension (mm)	45φ×280L		57φ×280L		
Priming volume (mL)		Approx. 82		Approx. 150		
Filled liquid		Sterile water				
Sterilization method		Gamma-ray irradiation				

Note

- Please read instructions carefully when using this product.
- All data presented herein are based on actual measurements performed by Kuraray Medical Inc., and manufacturer accept no liability or losses resulting from the use of or misuse of this information.
- EVACLIO™ is a trademark of SB-KAWASUMI LABORATORIES, INC.

Distributed by

CE 0123

Manufacturer
SB-KAWASUMI LABORATORIES, INC.
3-25-4 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8602, Japan
TEL +81-44-589-8070 URL www.sb-kawasumi.jp

Authorised representative in the European community
Medical Technology Promedt Consulting GmbH
Altenhofstrasse 80, 66386 St. Ingbert, Germany

Manufacturing facility
Kawasumi Laboratories (Thailand) Co., Ltd.

KLE-EC-2301-05-FF

Plasma Separator Evaclio™



S smaller loss of
high-molecular-weight
substances


High-volume
selective plasma exchange

Plasma substitute
fluid saving

 **SB-KAWASUMI**

Pore Size of EVACLIO™


There are four models of Evaclio™s with different pore size distribution: EC-1C, EC-2C, EC-3C and EC-4C, and the appropriate model can be selected depending on what kinds of substances should be removed. Pores of all these models are significantly small in size compared to those of the conventional plasma separators.



(*1) ※PC: Conventional Plasma separator
※EC-xA and current EC-xC are the same products.

Smaller Loss of High-molecular-weight Substances


Smaller pore size of the EVACLIO™ membrane results in smaller loss of high-molecular-weight substances such as albumin, immunoglobulins and coagulation proteins.



(*1) ※EC-xA and current EC-xC are the same product.

Plasma Substitute Fluid Saving


Since the EVACLIO™ can reduce the loss of albumin during plasma exchange treatment, it is possible to save the supply of albumin as substitute fluid.



*Substitute albumin amount is to be adjusted according to the patient's condition.
This contents described in the text are illustrated.
(*1)

High-volume Selective Plasma Exchange

Due to the smaller loss of albumin, substitute albumin to be supplemented per unit amount of exchanged plasma can be reduced. As a result, it may become possible to treat more plasma if the same amount of substitute albumin is supplemented as in the case that a conventional plasma separator is used. (The average amount of plasma treated in PE using a conventional plasma separator is between 3 and 4 liters.)




*This contents described in the text are graphed.
(*1)

Characteristics of a Hollow Fiber Membrane Material, EVOH

Excellent Antithrombogenicity

It is reported that a EVACLIO™ membrane material, ethylene vinyl alcohol copolymer (EVOH), shows excellent antithrombogenicity.



Bibliography

(*1) K Taniguchi, et al, Medical Science Digest Vol 28 (6), 2002 29(247)-33(251)
(*2) Naito H, et al, Jpn. J. Artif Organs 16 (2), 1987 763-766